In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking ...

Payers and employers have tightened access to the glucagon-like peptide-1 receptor agonist class once these therapies became ...

Tirzepatide shows promise in reducing weight and preventing diabetes progression in people with obesity and prediabetes, with ...

001). Notably, the trial demonstrated an association between tirzepatide treatment and improvements in glycemic control, cardiometabolic risk factors such as fasting insulin, blood pressure and ...

and Mounjaro® (tirzepatide) can help people lose weight, and some — like Wegovy® and Zepbound® — are FDA-approved for those with overweight or obesity and high blood pressure. Your ...

In an earlier analysis of the SURMOUNT-1 trial, tirzepatide was shown to provide substantial and sustained reductions in body weight in persons with obesity over a 72-week period. Here ...

Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave ... factors like fasting insulin and blood pressure as well as “health-related ...

There’s been lots of attention on type 2 diabetes drugs recently, especially since they might also be able to support weight ...

The research also identified changes in glycemic control and cardiometabolic components like lipids and blood pressure. The research found that tirzepatide was generally well-tolerated ...

A phase 3 trial found that Eli Lilly's tirzepatide significantly reduced ... improvements in several health markers, including blood pressure, insulin and lipids, with the effects sustained ...

In additional endpoints, the study showed an association of tirzepatide treatment with improved glycemic control, cardiometabolic risk factors (including fasting insulin, blood pressure ...